2.50
Hdl Handle:
http://hdl.handle.net/10541/86514
Title:
Faslodex (ICI 182780). an oestrogen receptor downregulator.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Anti-oestrogen therapy, tamoxifen in particular, has revolutionised the treatment of breast cancer. However, the partial agonist activity of tamoxifen is associated with an increased risk of endometrial cancer and the acquisition by patients of tamoxifen-resistance. In an attempt overcome these negative aspects of tamoxifen therapy, 'pure' anti-oestrogens have been developed and are currently being investigated for the treatment of breast cancer.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital NHS Trust, M20 4BX, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uk
Citation:
Faslodex (ICI 182780). an oestrogen receptor downregulator. 2000, 36 Suppl 4:S87-8 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Sep-2000
URI:
http://hdl.handle.net/10541/86514
DOI:
10.1016/S0959-8049(00)00241-0
PubMed ID:
11056334
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthonyen
dc.date.accessioned2009-11-19T15:30:59Z-
dc.date.available2009-11-19T15:30:59Z-
dc.date.issued2000-09-
dc.identifier.citationFaslodex (ICI 182780). an oestrogen receptor downregulator. 2000, 36 Suppl 4:S87-8 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid11056334-
dc.identifier.doi10.1016/S0959-8049(00)00241-0-
dc.identifier.urihttp://hdl.handle.net/10541/86514-
dc.description.abstractAnti-oestrogen therapy, tamoxifen in particular, has revolutionised the treatment of breast cancer. However, the partial agonist activity of tamoxifen is associated with an increased risk of endometrial cancer and the acquisition by patients of tamoxifen-resistance. In an attempt overcome these negative aspects of tamoxifen therapy, 'pure' anti-oestrogens have been developed and are currently being investigated for the treatment of breast cancer.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Receptorsen
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials, Phase II as Topic-
dc.subject.meshDown-Regulation-
dc.subject.meshEstradiol-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshReceptors, Estrogen-
dc.titleFaslodex (ICI 182780). an oestrogen receptor downregulator.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital NHS Trust, M20 4BX, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalEuropean Journal of Canceren
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.